Charity-funded research plays a key role in advancing new treatments for children with cancer. In this blog, we shine a spotlight on the MiNivAn trial, a pioneering project in our research portfolio.

Chair of Trustees, Nick Bird, has been awarded an MBE in the 2025 New Year Honours list for his exceptional services to research and advocacy for children affected by neuroblastoma.

As the government prepares it's 10 Year Health Plan, Solving Kids' Cancer has taken the opportunity to highlight the needs of children with cancer that must be recognised.

The neuroblastoma community plays a crucial role in raising awareness and generating much-needed funds for Solving Kids' Cancer UK.

This year we made our debut visit to the Labour and Conservative Party Conferences. Public Affairs & Advocacy Lead, Emily, reflects on the experience.

AMXT1501/DFMO (polyamine inhibition) therapy

A brand new support tool developed by Advanced Nurse Practitioner Helen Pearson is now available to parents facing difficult decisions in their child's treatment and care.

We're pleased to announce the extension of funding for the MiNivAn trial, investigating new combination therapies for children with relapsed or refractory high-risk neuroblastoma.

Solving Kids’ Cancer UK is proud to announce a new three-year charity partnership with Julius Baer International Ltd, the UK entity of one of the world’s leading wealth management firms.